Global Pharma Giants Concered About China’s New Anti-Monopoly Law
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors